Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P49711
UPID:
CTCF_HUMAN
Alternative names:
11-zinc finger protein; CCCTC-binding factor; CTCFL paralog
Alternative UPACC:
P49711; B5MC38; Q53XI7; Q59EL8
Background:
Transcriptional repressor CTCF, also known as 11-zinc finger protein, plays a pivotal role in chromatin structure and function, mediating transcriptional regulation and chromatin insulators. It binds to DNA sequence-specific sites, influencing gene expression by preventing enhancer and silencer interactions. CTCF's involvement in transcriptional repression and activation, chromatin remodeling, and epigenetic regulation underscores its multifaceted role in gene expression and cellular development.
Therapeutic significance:
The association of CTCF with Intellectual developmental disorder, autosomal dominant 21, highlights its potential as a therapeutic target. Understanding the role of Transcriptional repressor CTCF could open doors to potential therapeutic strategies, offering hope for interventions in genetic disorders linked to its dysfunction.